Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.

Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P, Berking C, Kämpgen E, Dippel E, Stadler R, Hauschild A, Fluck M, Terheyden P, Rompel R, Loquai C, Assi Z, Garbe C, Schadendorf D.

J Transl Med. 2015 Nov 6;13:351. doi: 10.1186/s12967-015-0716-5.

2.

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.

Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, Livingstone E, Bluhm L, Rompel R, Griewank KG, Fluck M, Schilling B, Schadendorf D.

PLoS One. 2015 Mar 11;10(3):e0118564. doi: 10.1371/journal.pone.0118564. eCollection 2015.

3.

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.

Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, Kämpgen E, Karaszewska B, Mauch C, Miller WH Jr, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, Swann S, Hauschild A.

Ann Oncol. 2014 Jul;25(7):1428-36. doi: 10.1093/annonc/mdu154. Epub 2014 Apr 25.

PMID:
24769640
4.

Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.

Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pföhler C, Schiller M, Hauschild A, Hein R, Kämpgen E, Kellner I, Leverkus M, Becker JC, Ströbel P, Schadendorf D.

Clin Cancer Res. 2014 Jan 15;20(2):499-510. doi: 10.1158/1078-0432.CCR-13-1411. Epub 2013 Oct 30.

5.

Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.

Baur AS, Lutz MB, Schierer S, Beltrame L, Theiner G, Zinser E, Ostalecki C, Heidkamp G, Haendle I, Erdmann M, Wiesinger M, Leisgang W, Gross S, Pommer AJ, Kämpgen E, Dudziak D, Steinkasserer A, Cavalieri D, Schuler-Thurner B, Schuler G.

Blood. 2013 Sep 26;122(13):2185-94. doi: 10.1182/blood-2012-09-456988. Epub 2013 Aug 19.

PMID:
23958949
6.

Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.

Becker JC, Andersen MH, Hofmeister-Müller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kämpgen E, Opitz A, Zapatka M, Bröcker EB, Thor Straten P, Schrama D, Ugurel S.

Cancer Immunol Immunother. 2012 Nov;61(11):2091-103. doi: 10.1007/s00262-012-1266-9. Epub 2012 May 8.

7.

Autocrine TNF is critical for the survival of human dendritic cells by regulating BAK, BCL-2, and FLIPL.

Lehner M, Kellert B, Proff J, Schmid MA, Diessenbacher P, Ensser A, Dörrie J, Schaft N, Leverkus M, Kämpgen E, Holter W.

J Immunol. 2012 May 15;188(10):4810-8. doi: 10.4049/jimmunol.1101610. Epub 2012 Apr 13.

8.

Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis.

Hundorfean G, Atreya R, Agaimy A, Heinzerling L, Kämpgen E, Schuler G, Neurath MF.

Endoscopy. 2012;44 Suppl 2 UCTN:E78-9. doi: 10.1055/s-0031-1291603. Epub 2012 Mar 6. No abstract available.

PMID:
22396291
9.

Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.

Knippertz I, Hesse A, Schunder T, Kämpgen E, Brenner MK, Schuler G, Steinkasserer A, Nettelbeck DM.

J Immunother. 2009 Jun;32(5):524-38. doi: 10.1097/CJI.0b013e3181a28422.

PMID:
19609245
10.

A fast and robust method to clone and functionally validate T-cell receptors.

Birkholz K, Hofmann C, Hoyer S, Schulz B, Harrer T, Kämpgen E, Schuler G, Dörrie J, Schaft N.

J Immunol Methods. 2009 Jul 31;346(1-2):45-54. doi: 10.1016/j.jim.2009.05.001. Epub 2009 May 7.

PMID:
19427315
11.

Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.

Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, Kämpgen E, Schuler G, Abken H, Schaft N, Dörrie J.

Gene Ther. 2009 May;16(5):596-604. doi: 10.1038/gt.2008.189. Epub 2009 Jan 22.

PMID:
19158846
12.

[Malignant melanoma of the lacrimal sac].

Heindl LM, Schick B, Kämpgen E, Kruse FE, Holbach LM.

Ophthalmologe. 2008 Dec;105(12):1146-9. doi: 10.1007/s00347-008-1740-0. German.

PMID:
18438631
13.

A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.

Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH.

Melanoma Res. 2008 Apr;18(2):73-84. doi: 10.1097/CMR.0b013e3282f7c8f9.

14.

Targeting HIV-1 Gag into the defective ribosomal product pathway enhances MHC class I antigen presentation and CD8+ T cell activation.

Goldwich A, Hahn SS, Schreiber S, Meier S, Kämpgen E, Wagner R, Lutz MB, Schubert U.

J Immunol. 2008 Jan 1;180(1):372-82.

15.

Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes.

Dörrie J, Schaft N, Müller I, Wellner V, Schunder T, Hänig J, Oostingh GJ, Schön MP, Robert C, Kämpgen E, Schuler G.

Cancer Immunol Immunother. 2008 Apr;57(4):467-77. Epub 2007 Sep 2.

PMID:
17768622
16.

Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses.

Schierer S, Hesse A, Müller I, Kämpgen E, Curiel DT, Schuler G, Steinkasserer A, Nettelbeck DM.

Int J Cancer. 2008 Jan 1;122(1):219-29.

17.

Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.

Erdmann M, Dörrie J, Schaft N, Strasser E, Hendelmeier M, Kämpgen E, Schuler G, Schuler-Thurner B.

J Immunother. 2007 Sep;30(6):663-74.

PMID:
17667530
18.

Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells.

Humrich JY, Thumann P, Greiner S, Humrich JH, Averbeck M, Schwank C, Kämpgen E, Schuler G, Jenne L.

Eur J Immunol. 2007 Apr;37(4):954-65.

19.

An improved method for RNA isolation and removal of melanin contamination from melanoma tissue: implications for tumor antigen detection and amplification.

Dörrie J, Wellner V, Kämpgen E, Schuler G, Schaft N.

J Immunol Methods. 2006 Jun 30;313(1-2):119-28. Epub 2006 May 16.

PMID:
16780866
20.

Mature monocyte-derived dendritic cells respond more strongly to CCL19 than to CXCL12: consequences for directional migration.

Humrich JY, Humrich JH, Averbeck M, Thumann P, Termeer C, Kämpgen E, Schuler G, Jenne L.

Immunology. 2006 Feb;117(2):238-47.

21.

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tüttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler G; DC study group of the DeCOG.

Ann Oncol. 2006 Apr;17(4):563-70. Epub 2006 Jan 17.

PMID:
16418308
22.

A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes.

Schaft N, Dörrie J, Müller I, Beck V, Baumann S, Schunder T, Kämpgen E, Schuler G.

Cancer Immunol Immunother. 2006 Sep;55(9):1132-41. Epub 2005 Dec 13.

PMID:
16344988
23.

Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation.

Schaft N, Dörrie J, Thumann P, Beck VE, Müller I, Schultz ES, Kämpgen E, Dieckmann D, Schuler G.

J Immunol. 2005 Mar 1;174(5):3087-97. Erratum in: J Immunol. 2005 May 1;174(9):5884.

24.

Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.

Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LØ, Rath JC, Böck M, Bröcker EB, Straten PT, Kämpgen E, Becker JC.

Vaccine. 2005 Jan 4;23(7):884-9.

PMID:
15603888
25.

Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.

Eggert AO, Andersen MH, Voigt H, Schrama D, Kämpgen E, Straten PT, Becker JC.

Eur J Immunol. 2004 Nov;34(11):3285-90.

26.

Shift from systemic to site-specific memory by tumor-targeted IL-2.

Schrama D, Xiang R, Eggert AO, Andersen MH, Pedersen Ls LØ, Kämpgen E, Schumacher TN, Reisfeld RR, Becker JC.

J Immunol. 2004 May 15;172(10):5843-50.

27.

Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression.

Terheyden P, Schrama D, Pedersen LØ, Andersen MH, Kämpgen E, thor Straten P, Becker JC.

Scand J Immunol. 2003 Nov;58(5):566-71.

28.

MHC class II-mediated apoptosis in dendritic cells: a role for membrane-associated and mitochondrial signaling pathways.

Leverkus M, McLellan AD, Heldmann M, Eggert AO, Bröcker EB, Koch N, Kämpgen E.

Int Immunol. 2003 Aug;15(8):993-1006.

PMID:
12882837
29.

Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes.

Kolb-Mäurer A, Kämmerer U, Mäurer M, Gentschev I, Bröcker EB, Rieckmann P, Kämpgen E.

FEMS Immunol Med Microbiol. 2003 Apr 1;35(3):255-62.

30.

Unique appearance of proliferating antigen-presenting cells expressing DC-SIGN (CD209) in the decidua of early human pregnancy.

Kämmerer U, Eggert AO, Kapp M, McLellan AD, Geijtenbeek TB, Dietl J, van Kooyk Y, Kämpgen E.

Am J Pathol. 2003 Mar;162(3):887-96.

31.

Visualization and characterization of migratory Langerhans cells in murine skin and lymph nodes by antibodies against Langerin/CD207.

Stoitzner P, Holzmann S, McLellan AD, Ivarsson L, Stössel H, Kapp M, Kämmerer U, Douillard P, Kämpgen E, Koch F, Saeland S, Romani N.

J Invest Dermatol. 2003 Feb;120(2):266-74.

32.

Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells.

Schrama D, Pedersen LØ, Keikavoussi P, Andersen MH, Straten Pt Pt, Bröcker EB, Kämpgen E, Becker JC.

J Invest Dermatol. 2002 Dec;119(6):1443-8.

33.

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.

Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB.

Br J Cancer. 2002 Oct 7;87(8):840-5.

34.

CC and CXC chemokines are differentially expressed in erythema multiforme in vivo.

Spandau U, Bröcker EB, Kämpgen E, Gillitzer R.

Arch Dermatol. 2002 Aug;138(8):1027-33.

PMID:
12164740
35.

Expression of functional kappa-opioid receptors on murine dendritic cells.

Kirst A, Wack C, Lutz WK, Eggert A, Kämpgen E, Fischer WH.

Immunol Lett. 2002 Oct 21;84(1):41-8.

PMID:
12161282
36.

Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique.

Grauer O, Wohlleben G, Seubert S, Weishaupt A, Kämpgen E, Gold R.

Histochem Cell Biol. 2002 Apr;117(4):351-62. Epub 2002 Feb 16.

PMID:
11976908
37.

Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression.

McLellan AD, Kapp M, Eggert A, Linden C, Bommhardt U, Bröcker EB, Kämmerer U, Kämpgen E.

Blood. 2002 Mar 15;99(6):2084-93.

PMID:
11877283
39.

Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture.

Eggert AO, Becker JC, Ammon M, McLellan AD, Renner G, Merkel A, Bröcker EB, Kämpgen E.

Eur J Immunol. 2002 Jan;32(1):122-7.

40.

Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression.

Andersen MH, Keikavoussi P, Bröcker EB, Schuler-Thurner B, Jonassen M, Søndergaard I, Straten PT, Becker JC, Kämpgen E.

Int J Cancer. 2001 Dec 15;94(6):820-4.

41.

[Cell therapy with dendritic cells].

Kämpgen E, Becker J, Bröcker EB.

Internist (Berl). 2001 Oct;42(10):1314-20. Review. German. No abstract available.

PMID:
11688150
42.

Interaction of Neisseria meningitidis with human dendritic cells.

Kolb-Mäurer A, Unkmeir A, Kämmerer U, Hübner C, Leimbach T, Stade A, Kämpgen E, Frosch M, Dietrich G.

Infect Immun. 2001 Nov;69(11):6912-22.

43.

[Nevus of Ota and choroid melanoma].

Terheyden P, Rickert S, Kämpgen E, Münnich S, Hofmann UB, Bröcker EB, Becker JC.

Hautarzt. 2001 Sep;52(9):803-6. German.

PMID:
11572072
44.

Antibodies against listerial protein 60 act as an opsonin for phagocytosis of Listeria monocytogenes by human dendritic cells.

Kolb-Mäurer A, Pilgrim S, Kämpgen E, McLellan AD, Bröcker EB, Goebel W, Gentschev I.

Infect Immun. 2001 May;69(5):3100-9.

45.

Differential susceptibility to CD95 (Apo-1/Fas) and MHC class II-induced apoptosis during murine dendritic cell development.

McLellan AD, Terbeck G, Mengling T, Starling GC, Kiener PA, Gold R, Bröcker EB, Leverkus M, Kämpgen E.

Cell Death Differ. 2000 Oct;7(10):933-8.

46.

Isolation, enrichment, and culture of murine epidermal langerhans cells.

Koch F, Kämpgen E, Schuler G, Romani N.

Methods Mol Med. 2001;64:43-62. doi: 10.1385/1-59259-150-7:43.

PMID:
21374248
47.

Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.

Terheyden P, Becker JC, Kämpgen E, Bröcker EB.

Melanoma Res. 2000 Oct;10(5):475-82.

PMID:
11095409
48.

Classical chemotherapy for metastatic melanoma.

Becker JC, Kämpgen E, Bröcker E.

Clin Exp Dermatol. 2000 Sep;25(6):503-8. Review.

PMID:
11044186
49.

Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential.

Gunzer M, Schäfer A, Borgmann S, Grabbe S, Zänker KS, Bröcker EB, Kämpgen E, Friedl P.

Immunity. 2000 Sep;13(3):323-32.

50.

Dendritic cell activation by danger and antigen-specific T-cell signalling.

McLellan AD, Bröcker EB, Kämpgen E.

Exp Dermatol. 2000 Oct;9(5):313-22. Review.

PMID:
11016851

Supplemental Content

Loading ...
Support Center